Investing in Vietnam's healthcare: A guide for investors in 2026

Vietnam's healthcare sector has reached a rare inflection point: demand is accelerating, capital is available, and regulation is being rewritten at historic speed. Yet capital alone cannot buy scale here. The true constraints are human capital, regulatory navigation, and systemic design, not demand or funding. 

This article synthesizes insights from the expert-led event "Investing in Vietnam's Healthcare Sector: Market Trends, Investor Insights, AI Applications, and Key Legal & Tax Considerations," bringing together perspectives from investors, operators, technology partners, and advisors. Understanding this opportunity requires a shift in lens: from asset acquisition to system design, from hospital expansion to integrated delivery, and from capital deployment to operational orchestration. 

1. A structural, not cyclical, rise in healthcare demand 

Across Southeast Asia, five forces are converging fastest in Vietnam: 

• Macroeconomic tailwinds: Vietnam is among the top 10 fastest-growing global economies, with strong FDI inflows into healthcare infrastructure and rising disposable income shifting demand toward higher-quality, specialized services. 
• Epidemiological transition: ~81% of mortality now stems from non-communicable diseases, with double-digit growth in conditions like diabetes, COPD, and heart failure. 
• Rising utilization: Healthcare spending per capita grew at a ~8.9% CAGR (2017–2027), even as hospital beds, nurses, and physicians remain well below WHO-recommended levels. 
• Policy support: Government initiatives promote digital healthcare and public–private partnerships to supplement public infrastructure. 
• Industrial localization: Vietnam targets ~80% local pharmaceutical production by 2030 (vs. ~50% in 2020), positioning Southeast Asia as a manufacturing hub. 

These are structural shifts, not cyclical tailwinds, and Vietnam stands out because they are converging here faster and more visibly than elsewhere in the region. 

2. Why capital alone cannot buy scale? 

Three structural forces define Vietnam's healthcare moment: a rising middle class demanding private care, a rapidly aging population, and a digitally native society intolerant of fragmented service delivery. As families urbanize and have fewer children, chronic disease management is shifting from the family unit to institutional care, but the disease burden is shifting too: ~40% of the population is pre-diabetic, and over 70% of 12th-grade students suffer from myopia. 

"As Vietnam develops, it is undergoing an 'epidemiological transition' where the disease burden rapidly shifts from infectious disease to chronic illness.", Zig Wronsky, Tremont Capital Ventures 

The real bottleneck is clinician supply, not capital. Physician density sits at roughly ⅓ of U.S. levels; Vietnam has only 609 licensed psychiatrists nationwide; HCMC has 2–3× more doctors per capita than many provinces; and training a specialist takes a minimum of 10 years. 

More critically, a hospital's operating license is legally tied to its head doctor. If that clinician leaves, the facility's regulatory standing is compromised and licensing must effectively restart. For investors, this means value depends on retaining licensed leadership, not just owning facilities. 

3. Legal and structural constraints investors must price in 

• Foreign-invested status is triggered once foreign investors hold more than 50% of an operating company's charter capital, changing licensing, land, and expansion rules. 
• Capital thresholds rise accordingly: ~USD 20 million for hospitals, ~USD 2 million for policlinics, ~USD 200,000 for specialty clinics, regardless of actual foreign stake. 
• Pharmaceutical distribution is off-limits to foreign investors, including hospital pharmacies, often forcing post-deal restructuring of pharmacy and revenue models. Manufacturing and hospital/clinic ownership carry no foreign cap. 
• Drug pricing and compliance are tightly regulated: each drug needs market authorization, margins are capped, and prescription sales require record-keeping. 
• Licensing is tied to named clinicians (chief doctor/pharmacist), making retention, via service agreements, KPI-linked earn-outs, and call/put options, central to post-merger integration. 
• Land and real estate carry hidden risk: government land allocations may need conversion to long-term leases, and hospitals on residential/commercial land face zoning and relocation pressure. 
• Multiple regulatory clearances apply to M&A, Department of Finance approval, merger control, and sub-license amendments. 
• Sub-licenses (lab testing, imaging, dialysis, vaccination, telemedicine, pharmacy) are separate from the main operating license, and gaps can delay integration or expansion. 

4. Regulatory reform is making the market more predictable 

In a single year, Vietnam cut government ministries from 18 to 14 and passed a record 86 laws to modernize the economy. 

"This has produced a paradoxical outcome: fewer institutions, but significantly deeper regulatory throughput.", Dao Thu Nga, Sanofi Vietnam 

The Reliance Principle, recognizing approvals from trusted international regulators, is shortening the historic 8–10-year lag in drug and medical technology time-to-market. Under Decision 1165/QĐ-TTg (National Pharmaceutical Industry Development Strategy to 2030, vision to 2045), targets are explicit: 100% health insurance coverage by 2030, life expectancy of 75 by 2030 (80+ by 2045), and free annual check-ups by 2026. 

Four foundational resolutions set the reform direction, Resolution 66-NQ/TW (legal reform), Resolution 68-NQ/TW (private sector development), Resolution 57-NQ/TW (science and innovation), and Resolution 59-NQ/TW (international integration). For healthcare specifically, Resolution 72-NQ/TW reframes healthcare as national infrastructure, mandating minimum staffing of 4–5 doctors per communal health station and expanded primary-care insurance. 

The 2024 amended Health Insurance and Tender Laws improved procurement flexibility and pricing transparency. The new Pharma Law (Law No. 44/2024/QH15), effective 1 July 2025, is the most structural shift in decades, simplifying renewals and shifting promotion to a self-responsibility model. 

For investors: the opportunity lies less in rapid liberalization and more in a steady move toward a structured, execution-focused market, though uncertainty remains around pricing, insurance funding, and reimbursement cadence (notably the NRDL Circular expected in 2026). 

5. Scaling in a more predictable market: integration over aggregation 

Vietnam's challenge is a platform mismatch: large PE funds need institutional-grade operating platforms for USD 100M+ deals, but the market is dominated by founder-led clinics lacking standardized governance. The scalable model is integration, not expansion, via Integrated Delivery Networks (IDNs): 

• Hub: tertiary hospitals for complex, high-acuity care 
• Spokes: specialty outpatient clinics for volume and efficiency 
• MSO layer: centralized technology, compliance, HR/credentialing, and finance 

This decouples clinical excellence from operational complexity, unlocking asset-light expansion, physician focus, and institutional-grade consolidation. As IPO markets reopen, platform depth, not footprint size, will determine winners. 

6. AI and horizontal platforms: the new operating-system layer 

Scale doesn't fail from lack of demand or capital, it fails because there's no shared operational language across fragmented clinics. Horizontal platforms like Cognisian unify patient journey data, operational intelligence, and AI-driven decision support into a single layer usable by operators and investors, addressing a persistent execution gap in PE-backed healthcare groups. 

"Intelligent data capture through technology becomes the foundation of consistent, scalable care... the clinic or hospital becomes the model, and [AI] becomes the decision engine.", Prithvi Puttaraju, CEO, Cognisian AI Healthcare 

In augmented ophthalmology, AI enables mass retinal screening (up to 5,000 patients/day), early detection of diabetes, cardiovascular disease, and neurodegeneration, and a 10× shift in physician productivity, proof that Vietnam's clinician scarcity is becoming a technology-first advantage. 

7. Why healthcare deals fail, and what wins 

Investor expectations (30–50% growth, EBITDA focus, standardization) routinely clash with medical reality (7–10% sustainable growth, deep clinical autonomy, decades-old hospital cultures). Most healthcare deals break in the corridors, not the numbers, through cultural resistance, talent attrition, and operational drag. 

"Without operational readiness and strong governance frameworks, M&A merely shifts embedded risks from the seller to the buyer.", Laurent Nguyen, Head of Financial Advisory, Forvis Mazars Vietnam 

The winning operator's playbook: treat compliance as a prerequisite, build platforms rather than rely on star doctors, partner rather than build AI in-house, anticipate operational friction proactively, and stay disciplined on EBITDA. Leading operators are also converging on a 5P model, Preventive, Predictive, Personalized, Participatory, Platform-based, moving from hospital-centric to journey-centric care. 

"The current model cuts the patient into specialties. The future model manages the patient journey.", Dr. Su Le, CEO, Xuyen A Hospital Group 

8. Key takeaways and what comes next for Vietnam 

• Healthcare demand in Vietnam is structural, driven by an aging population and a shift from infectious to chronic disease. 
• Clinician supply, not capital, is the real bottleneck; hospital licenses are legally tied to named practitioners. 
• Foreign-invested status (triggered above 50% OpCo ownership) raises capital thresholds and changes licensing and land rules; drug distribution remains off-limits to foreign investors. 
• Regulatory reform (Resolutions 66/68/57/59/72, Decision 1165/QĐ-TTg, the new Pharma Law, and the Reliance Principle) is making Vietnam's market more predictable, not just more open. 
• Integrated Delivery Networks and MSO structures, not standalone hospital expansion, are the scalable model. 
• AI-enabled horizontal platforms are becoming the operational backbone for consistent, auditable scale. 
• Most failed deals break down in post-merger integration and governance, not valuation. 

Vietnam's healthcare market has reached a point where the fundamentals are no longer in question. Demand is structural, capital is available, policy direction is explicit, and regulatory execution is accelerating, the conditions for scale now exist. What remains unresolved is not whether the opportunity is real, but whether it will be translated into durable, integrated care systems. The next phase will be defined by execution: the ability to design platforms, align talent with governance, and scale without compromising clinical integrity. The question ahead is simple, but decisive: who will move beyond asset accumulation and build the operating systems capable of turning momentum into lasting healthcare outcomes? 

How we can help

Getting the structure right is the first step to investing or operating in Vietnam's healthcare sector. Forvis Mazars Vietnam's financial advisory, legal, tax, and accounting teams support investors and operators through market entry structuring, regulatory due diligence, and post-merger integration. 

Contact our team to assess your investment structure and build a compliant, scalable operating model for Vietnam's healthcare market.